Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
12/2005
12/08/2005WO2002066494A3 Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade
12/08/2005US20050272918 Method of treating allergy using antibody against human interleukin-5 receptor alpha chain
12/08/2005US20050272915 Skrp, astray, string, vacm associated with metabolic control
12/08/2005US20050272815 Compounds and compositions for delivering active agents
12/08/2005US20050272798 Analogues of rachelmycin and the duocarmycins that are potent cytotoxins containing a benzodipyrrole or naphthopyrrole ring; anticancer agents
12/08/2005US20050272780 Small molecule inhibitors of rotamase enzyme activity
12/08/2005US20050272738 Combined treatment with oxaliplatin and an epidermal growth factor receptor kinase inhibitor
12/08/2005US20050272710 Providing sustained systemic concentrations of therapeutic or prophylactic agents such as gamma-aminobutyric acid derivatives following oral adiminstration to animals
12/08/2005US20050272703 Anti-tumor agents
12/08/2005US20050272684 Breast cancer resistance protein (BCRP) and the DNA which encodes it
12/08/2005US20050272683 Antisense oligonucleotides against thymidylate synthase
12/08/2005US20050272676 Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
12/08/2005US20050272669 treatment of disease associated with hyperglycemia: diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity; e.g. -[(4-{3-[N-(Carbamoylmethyl)-N-(methanesulfonyl)amino]-propoxy}-2-methylphenyl)methyl]-3-( beta -D-glucopyranosyloxy)-5-isopropyl-1H-pyrazole
12/08/2005US20050272668 Anti-inflammatory compositions and methods
12/08/2005US20050272667 Analogs and derivatives of (S,S,R)-(-)-actinonin and uses therefor
12/08/2005US20050272666 Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
12/08/2005US20050272664 Methods for inhibiting angiogenesis and or lymphangiogenesis
12/08/2005US20050272663 Novel substituted prolines as inhibitors of hepatitis C virus NS3 serine protease
12/08/2005US20050272662 Self-assembled peptide-amphiphiles & self-assembled peptide nanofiber networks presenting multiple signals
12/08/2005US20050272661 providing a neo-tryptophan derivative, andlinking amino acid residues to said neo-tryptophan derivative to form neurotensin polypeptide containing neo-tryptophan
12/08/2005US20050272660 Polypeptide derivatives of parathyroid hormone (PTH)
12/08/2005US20050272659 Helical peptidomimetics with enhanced activity
12/08/2005US20050272658 Applications of peptides derived from the cytoplasmic domain of amyloid precursor protein (APP)
12/08/2005US20050272657 Human growth hormone aqueous formulation
12/08/2005US20050272656 Stimulating hematopoiesis
12/08/2005US20050272655 Neonatal Onset Multisystem Inflammatory Disorder, Muckle-Wells Syndrome, Familial Cold Autoinflammatory Syndrome, familial mediterranean fever, tumor necrosis factor receptor-associated periodic fever syndrome, or systemic onset juvenile idiopathic arthritis; interleukin fusion protein antagonist
12/08/2005US20050272654 NF-kappaB activation inhibitors, and their pharmaceutical uses
12/08/2005US20050272653 Bone morphogenic protein fusion for use in treatment and prevention of bone disorders
12/08/2005US20050272652 Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
12/08/2005US20050272651 Methods for treating breast cancer using NRIF3 related molecules
12/08/2005US20050272650 Materials and methods for treatment of inflammatory and cell proliferation disorders
12/08/2005US20050272649 Conjoint administration of morphogens and ACE inhibitors in treatment of chronic renal failure
12/08/2005US20050272648 Ghrelin analogs
12/08/2005US20050272647 Arthrodial cartilage extracellular matrix degradation inhibitor
12/08/2005US20050272646 Cyclic peptide antibiotic wherein antibiotic is a streptogramin Type B derivative and is characterized by the replacement of an enzyme sensitive ester bond with a stable bond selected from an amide, N-methyl amide, enamine and sulfonamide bond
12/08/2005US20050272645 Isolated polypeptide; nonhemolytic, minimal in vitro cytotoxicity
12/08/2005US20050272644 Method for increasing therapeutic gain in radiotherapy and chemotherapy
12/08/2005US20050272643 Removal of serum albumin from human serum or plasma
12/08/2005US20050272642 Protecting a muscarinic acetylcholine receptor in Alzheimer patients from oxidative stress, detoxification from toxic metal, by administering at least one pyrophosphates; prevent tissue damage, increasing the efficacy of a therapeutic agent
12/08/2005US20050272641 Therapeutic agents for diabetes
12/08/2005US20050272640 Combined control of insulin bolus dosing and basal delivery for the goal of achieving normal glycemic response to meals, exercise, stressors, and other perturbations to blood glucose levels
12/08/2005US20050272639 Crystalline polymorph of the pentahydrate form in synergistic combination with another active ingredient to enhance drug delivery; antidiabetic agents
12/08/2005US20050272638 Improved bioavailability; for oral and intracolonic administration
12/08/2005US20050272637 Compositions and methods for modulating signaling mediated by IGF-1 receptor and erbB receptors
12/08/2005US20050272636 Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma
12/08/2005US20050272635 Use of corticotroph-derivced glycoprotein hormone to treat liver steatosis
12/08/2005US20050272634 for stimulating physiological mobilization, proliferation and differentiation of endothelial progenitor cells, vasculogenesis; diabetic wound healing
12/08/2005US20050272633 Derivatives of the nf-kappab inducing enzyme, their preparation and use
12/08/2005US20050272161 Fixed-dried red blood cells or blood platelets carrying an active agent which, upon reconstitution, adhere to thrombogenic surfaces, undergo shape change, form a hemostatic plug, and release their granular contents
12/08/2005US20050272156 Utilizes one or more sets of electrodes spaced to hold surface tension of sample receiving pulses; for gene discovery/therapy/tissue engineering
12/08/2005US20050272128 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
12/08/2005US20050272127 Antibody against an angiogenesis-inhibiting peptide homologous to human ChM1L chondromodulin-I (ChM-I); hybridomas; diagnostic kits; controlling angiogenesis
12/08/2005US20050272119 Polypeptides having 2',5'-oligoadenylate phosphodiesterase activity, antibodies against polypeptides, polynucleotides coding for polypeptides, recombinant plasmid DNAs into which polynucleotides have been inserted; for searching for antitumor agents, viricides
12/08/2005US20050272118 biological conjugated drug binding with a detectable label, or toxin maytansine and calicheamicin; monoclonal antibody as antiinflammatory agents in the therapeutic treatment and diagnostic detection of immune disorders in mammals; biodrugs
12/08/2005US20050272099 Nucleic acids encoding androgen receptorl drug screening
12/08/2005US20050272083 EGFR mutations
12/08/2005US20050272077 Cytokine-, stress-, and oncoprotein-activated human protein kinase kinases
12/08/2005US20050272048 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
12/08/2005US20050272040 Method for increasing synaptic growth or plasticity
12/08/2005US20050272038 Compositions and methods for diagnosis and therapy of cancers
12/08/2005US20050272028 Myostatin and mimetics thereof
12/08/2005US20050271754 Composition for prevention or treatment of an alcohol hangover
12/08/2005US20050271747 Combined treatment with cisplatin and an epidermal growth factor receptor kinase inhibitor
12/08/2005US20050271744 Comprising a peptide fraction which is preferably rich in di- and tripeptides in combination with an insulin sensitizer, preferably a natural or pharmaceutical insulin sensitizer; suitable as pharmaceutical or food or a food supplement; especially useful for Type 2 diabetes
12/08/2005US20050271728 High molecular weight medicine-containing preparation in powder form for administration through mucosa
12/08/2005US20050271726 Immune enhancing compositions and methods of use thereof
12/08/2005US20050271722 complex composed of a protein and/or peptide and a gallic acid ester that allow for sustained delivery of the protein or peptide in vivo upon administration of the complex; gallic acid ester is epigallocatechin gallate
12/08/2005US20050271719 Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
12/08/2005US20050271715 Conjugate having a cleavable linkage for use in a liposome
12/08/2005US20050271702 polyglycolic acid or polylactic acid or glycolic acid-lactic acid copolymer as biocompatible polymer having dispersed therein about 3%-5% (w/w) exendin-4 and about 2% (w/w) sucrose; antidiabetic agent
12/08/2005US20050271697 Local delivery of growth factors for stem cell transplantation
12/08/2005US20050271696 Medical device having a surface including a biologically active agent therein, and methods
12/08/2005US20050271681 Isolated FrpB nucleic acid molecule and vaccine
12/08/2005US20050271679 Recombinant adenylate cyclase toxin of Bordetella induces T cell responses against tumoral antigens
12/08/2005US20050271677 inhibiting Flavivirus infection by inhibiting the fusion between the virion envelope and a cell membrane; E1 envelope glycoprotein of hepaciviruses and E2 envelope glycoprotein of pestivirus have previously undescribed structures, truncated class II fusion proteins
12/08/2005US20050271673 Trifunctional reagent for conjugation to a biomolecule
12/08/2005US20050271667 Identification of a novel endothelial-derived gene EG-1
12/08/2005US20050271666 Regulation of human protein phosphatase IIc-like enzyme
12/08/2005US20050271664 Antibodies for inhibiting blood coagulation and methods of use thereof
12/08/2005US20050271661 Synergistic mixture with glucocorticoid receptors antagonist
12/08/2005US20050271659 Novel T-cell membrane protein (TIRC7), peptides and antibodies derived therefrom and uses thereof
12/08/2005US20050271654 Antibody purification
12/08/2005US20050271651 Inhibition of bright function as a treatment for excessive immunoglobulin production
12/08/2005US20050271650 Method and composition for angiogenesis inhibition
12/08/2005US20050271648 Carbon nanotube structure and production method thereof
12/08/2005US20050271647 Chimeric pro-caspases and methods of using same
12/08/2005US20050271646 Fibrin material and method for producing and using the same
12/08/2005US20050271645 combination of lysozyme with an antibiotic: Ampicillin, Sulbactam, Cefotaxime, Ceftriaxone, Cefepime, Imipenem, Meropenem, Piperacillin, Tazobactam, Azithromycin, Clarithromycin, Erythromycin, Vancomycin, Clindamycin, Gatofloxicin, Levofloxacin, Moxifloxacin, Ciprofloxacin etc. to treat pneumonia
12/08/2005US20050271644 Vitamin K epoxide recycling polypeptide VKORC1, a therapeutic target of coumarin and their derivatives
12/08/2005US20050271634 Growth factor therapy mobilization of stem cells into the peripheral blood
12/08/2005US20050271633 Issue defect augmentation and repair with in vitro cultured fibroblasts
12/08/2005US20050271632 Methods of modulating hair growth
12/08/2005US20050271631 Material compositions and related systems and methods for treating cardiac conditions
12/08/2005US20050271626 Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway
12/08/2005US20050271625 RAAV-neprilysin compositions and methods of use
12/08/2005US20050271624 Use of apoptosis inducing agents in the treatment of (auto) immune diseases
12/08/2005US20050271623 Reduction of dermal scarring
12/08/2005US20050271621 Ablated slam-dependent entry
12/08/2005US20050271619 Isolated nucleic acid molecules which encode T cell inducible factors, or interleukin-21, the proteins encoded, and uses thereof
12/08/2005US20050271618 Methods of reducing aggregation of IL-1ra
1 ... 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 ... 3163